Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease.

{
  "signal_id": "f605a826-bc7c-4663-9b7f-2665e6933f81",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-04-14T13:15:00+00:00",
  "company": {
    "name": "Illumina",
    "domain": "illumina.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/illumina-and-the-center-for-data-driven-discovery-in-biomedicine-bring-genomic-data-and-scalable-software-to-the-fight-against-pediatric-cancer-and-rare-disease-302741288.html",
    "title": "Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease.",
    "excerpt": "Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease.\n\nApr 14, 2026, 09:15 ET\n\nDataset will drive crucial insights to accelerate scientific discovery and ultimately improve pediatric patient care.\n\nSAN DIEGO, April 14, 2026 /PRNewswire/ - Illumina (NASDAQ: ILMN) and the Center for Data-Driven Discovery in Biomedicine (D3b) today announced a data partnership to advance research in pediatric cancer and rare disease. Through cloud-based data platforms, the global research community can unify and analyze pediatric data within a single, scalable discovery environment, enabling real-time, cross-cohort analysis and accelerating translation to clinical care.\n\nThrough this initiative, D3b is analyzing 100,000 whole genomes from pediatric patients using Illumina software solutions. This is one of the largest unified genomic datasets ever assembled. D3b and Illumina are enabling discovery at a scale not previously possible, making the resulting insights available through the Gabriella Miller Kids First Data Resource Center (Kids First DRC). This data empowers researchers and clinicians to uncover the biological origins of rare disease and cancer and translate findings for pediatric precision medicine.\n\nCongenital conditions and cancers are a leading cause of death in children yet...",
    "summary": "Illumina, Inc. partnered with The Children's Hospital of Philadelphia on Apr 14th '26.",
    "category": "partners_with",
    "found_at": "2026-04-14T13:15:00Z",
    "planning": false,
    "image_url": "https://mma.prnewswire.com/media/1876671/Illumina_Logo.jpg?p=facebook",
    "confidence": 0.5489,
    "published_at": "2026-04-14T14:15:00Z",
    "effective_date": "2026-04-14",
    "article_sentence": "SAN DIEGO, April 14, 2026 /PRNewswire/ - Illumina (NASDAQ: ILMN) and the Center for Data-Driven Discovery in Biomedicine (D3b) today announced a data partnership to advance research in pediatric cancer and rare disease."
  }
}

curl https://signals.autobound.ai/v1/signals/f605a826-bc7c-4663-9b7f-2665e6933f81 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"illumina.com","limit":20}'